IDO1 and non-small cell lung carcinoma: When IDO1 activity is expressed as kynurenine to tryptophan ratio, higher IDO activity was associated with shorter PFS and OS in 26 patients with non-small-cell lung carcinoma (NSCLC) treated with nivolumab monotherapy.40